Cellectricon Broadens Discovery Capabilities with Launch of Neurotoxicity Testing Services

New services offering enables early assessment of compound safety and neurotoxic risk in drug discovery


Cellectricon launches Neurotoxicity Testing Services.

 
MOLNDAL, SWEDEN (October 30, 2025) – Cellectricon, a services provider dedicated to advancing neuroscience drug discovery, today announced the launch of its new Neurotoxicity Testing Services; expanding its established neuroscience discovery platform to support the early safety assessment of drug candidates. Reflecting growing interest and feedback from the neuroscience community, the new service empowers drug developers to detect potential neurotoxic effects sooner—reducing risk, saving time, and improving confidence in candidate selection.
 
The new Neurotoxicity Testing Services draw directly on Cellectricon’s longstanding neuroscience expertise and portfolio of validated in vitro models. Clients can benefit from assays integrating optical electrophysiology, high-content imaging, and microfluidic systems. The result is an ability to evaluate a broad range of acute and chronic neurotoxicity endpoints; including neuronal excitability, neurite outgrowth, metabolic activity, cytokine release, and cellular phenotype.
 
By combining these advanced technologies with high-capacity assay formats, Cellectricon empowers drug developers to front-load safety evaluation across diverse therapeutic modalities—enabling the identification of neurotoxic effects earlier in the discovery pipeline.
 
“In recent years, we’ve seen growing demand for early-stage neurotoxicity testing—particularly from teams developing oligonucleotide-based drugs, who often face challenges in obtaining reliable, accurate assessments.” said Mattias Karlsson, Chief Executive Officer at Cellectricon. “We recognized that our existing validated assays were exceptionally well suited to address these needs. By building on our trusted assays and in vitro models, we’re proud to offer a robust solution that helps our clients make safer, faster decisions with greater confidence.”
 
Cellectricon will be showcasing its Neurotoxicity Testing Services, along with its established Neuroscience Service Modules, at BIO-Europe 2025 (November 3-5, Vienna, Austria) and at Neuroscience 2025 (Stand #528, November 15-19, San Diego, USA).
 
Cellectricon will also be hosting a live webinar titled “In Vitro Neuronal Models for Assessment of Acute and Delayed Onset Toxicity Effects of Oligonucleotide-Based Drugs” on Wednesday November 12th between 16.00 and 16.30 CET. The session will explore how in vitro neuronal models can be used to assess neurotoxicity mechanisms, improve translational relevance, and de-risk oligonucleotide drug development. Register for the free webinar here: https://cellectricon.com/neurotoxicity-webinar/
 
For more information on Cellectricon’s Neurotoxicity Testing Services, please visit:
https://cellectricon.com/our-services/neurotoxicity/

About Cellectricon
Founded in 2003, Cellectricon is a neuroscience-focused drug discovery services company based in Mölndal, Sweden. The company’s mission is to advance drug discovery through scientifically robust and physiologically relevant in vitro research solutions. Combining deep expertise in neurobiology with the latest advanced technologies, Cellectricon develops and delivers customized assays and models for target discovery, lead optimization, and safety evaluation. Working in close collaboration with pharmaceutical, biotech, and academic partners worldwide, Cellectricon helps accelerate early-stage R&D, reduce risk, and improve the translational relevance of preclinical discoveries.

For more information about Cellectricon, visit https://cellectricon.com